Page 11234..10..»

Archive for the ‘Stem Cell Tourism’ Category

Saudi Arabia Health Insurance Market Size, Share, Competitive Analysis and Growth by 2026 The Manomet Current – The Manomet Current

Tuesday, July 6th, 2021

According to the latest report by IMARC Group, titled Saudi Arabia Health Insurance Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026, the saudi arabia health insurance market reached a value of around US$ 6 Billion in 2020. Looking forward, IMARC Group expects the Saudi Arabia health insurance market to exhibit strong growth during the next five years.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Request Free Report Sample:

https://www.imarcgroup.com/saudi-arabia-health-insurance-market/requestsample

Health insurance refers to a type of insurance coverage that wholly or partially covers the medical and surgical expenses of an insured individual. It reimburses the medical and surgical expenses incurred for the treatment of injuries or illness to the insurer or pays for the same to the care provider directly. The insurer must develop a routine premium structure to pay for the opted insurance plan to avail numerous benefits at an affordable price point. Health insurance can also include additional services like diagnosis, medical check-ups, dental care, psychiatric care, treatment for chronic ailments, emergency transportation, and in-patient and daycare management.

Saudi Arabia Health Insurance Market 2021-2026 Competitive Analysis and Segmentation:

Competitive Landscape With Key Players:

The competitive landscape of the saudi arabia health insurance market has been studied in the report with the detailed profiles of the key players operating in the market.

Key Market Segmentation:

The report has segmented the saudi arabia health insurance market on the basis of type and service provider.

Breakup by Type:

Breakup by Service Provider:

Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/saudi-arabia-health-insurance-market

Key highlights of the report:

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Browse Related Reports:

India Facility Management Market: https://www.imarcgroup.com/india-facility-management-market

Gardening Equipment Market: https://www.imarcgroup.com/gardening-equipment-market

Eucalyptus Essential Oil Market: https://www.imarcgroup.com/eucalyptus-essential-oil-market

Fall Protection Equipment Market: https://www.imarcgroup.com/fall-protection-equipment-market

UAE Health Insurance Market: https://www.imarcgroup.com/uae-health-insurance-market

Baler Market: https://www.imarcgroup.com/baler-market

Bone Densitometer Market: https://www.imarcgroup.com/bone-densitometer-market

Hearing Aid Market: https://www.imarcgroup.com/hearing-aid-market

Stem Cell Banking Market: https://www.imarcgroup.com/stem-cell-banking-market

Endoscopy Devices Market: https://www.imarcgroup.com/endoscopy-devices-market

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US:

IMARC Group30 N Gould St, Ste RSheridan, WY 82801, USAEmail: sales@imarcgroup.comAmericas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800

Read the original:
Saudi Arabia Health Insurance Market Size, Share, Competitive Analysis and Growth by 2026 The Manomet Current - The Manomet Current

Read More...

Biobanks Market | Prominent Factors Analysis that will Help in Reshaping the Market Growth – BioSpace

Thursday, February 4th, 2021

Biobanks are essentially repositories for storing biological substances derived from humans, which may include organs, bio-specimens, plasma, saliva, and blood. With a vast rise in the number of organ replacement surgeries globally and significant advancements made in the fields of transfusion and replacement technologies, the role of the biobanks market has become more concrete in the healthcare sector in recent years.

The global biobanks market has witnessed expansion at a significant pace in the recent years owing to the vast rise in prevalence of a number of chronic diseases and the increased demand for personal medicine. The massive rise in incidence rate of conditions such as diabetes, cancer, neurovascular diseases, cardiovascular diseases, and respiratory diseases has compelled government bodies to take stronger actions in terms of investments in biobanks and increasing awareness about them. The global market for biobanks works in coherence with these efforts by adding pace to the process of drug discovery and the treatment of chronic diseases that are caused by activities such as smoking, consumption of alcohol, obesity, and unhealthy lifestyles.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2321

Heavy investment by a proactive government has boosted the North America biobanks market to the leading position in the global biobanks market, followed closely by Europe. Both regions are home to several bioscience companies and host a large number of drug discovery and research activities. Asia Pacific still remains the region with the most promising growth potential as the region shown high promise owing to an increase in investments from both government and non-government organizations, along with a large and increasingly affluent population base that is gaining awareness about the market.

Global Biobanks Market: Overview

The global biobanks market owes its conception to the rising need for replacement organs and the steady advancement in the replacement and transfusion technologies regarding a number of bodily substances. Though the technology and need to store organs and other bio-entities had been available for a long time, the global biobanks market took on a more important role in the healthcare sector following the increasing research in genomics. In the new millennium, the development of the personalized medicine field has been the vital driver for the global biobanks market. The likely advancement of the latter, thanks to helpful government regulations, is likely to make the crucial difference for the global biobanks market in the near future.

The steady technological advancement in the healthcare sector in the last few decades has now led to a scenario where the full potential of biobanks can be harnessed. As a result, the global biobanks market is projected to exhibit steady growth over the coming years.

Global Biobanks Market: Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=2321&ltype=S

The utilization of biobanks in stem cell research has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market include BioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2321

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Excerpt from:
Biobanks Market | Prominent Factors Analysis that will Help in Reshaping the Market Growth - BioSpace

Read More...

Update on the latest sports – Newscenter1.tv

Thursday, December 3rd, 2020

NFL-NEWS

Goodell: NFL committed to finishing regular season on time

UNDATED (AP) NFL Commissioner Roger Goodell says the league remains committed to finishing the regular season as scheduled. Goodell also said on a conference call that while the NFL is considering a bubble format for the playoffs, although it wouldnt necessarily resemble what the NHL and NBA used successfully in completing their seasons.

The leagues chief football administrative officer, stressed that the NFL plans to finish the schedule within the original 17-week format.

In other NFL news:

Quarterbacks Drew Lock and Brett Rypien (RIH-pihn) returned to the Denver Broncos practice Wednesday after coming off the reserve/COVID-19 list while the Broncos isolated practice squad veteran Blake Bortles. All three quarterbacks were banned from last weekends game against the New Orleans Saints after failing to wear their masks around quarterback Jeff Driskel, who tested positive for the coronavirus on Thanksgiving. The Broncos returned rookie receiver Kendall Hinton to their practice squad. Hinton filled in for Lock on Sunday when he completed just one of nine passes and was intercepted twice. Lock praised Hinton for his emergency QB work Sunday.

The Green Bay Packers have activated rookie linebacker Krys Barnes from the reserve/COVID-19 list. Barnes has missed three straight games since getting placed on that list Nov. 6. The undrafted free agent from UCLA has 48 tackles.

The Cleveland Browns are dealing with another COVID-19 case after an unidentified staff member tested positive. The team closed its facility Wednesday to conduct contact tracing, which has become routine the past two weeks because of several other positive tests. The Browns are expected to practice indoors after heavy snow in the Cleveland area. They activated star defensive end Myles Garrett from the reserve/COVID-19 list on Tuesday and expect him to practice as they get ready to play at Tennessee on Sunday. Garrett missed two games after becoming infected.

Quarterback Mike Glennon is getting another start for the Jacksonville Jaguars even though Gardner Minshew is healthy. Coach Doug Marrone says Minshew has been cleared to practice in full after recovering from a sprained thumb on his throwing hand, but hes sticking with Glennon at Minnesota on Sunday. Glennon was solid in his first start since Week 4 of the 2017 season.

The Buffalo Bills are in position to get healthier for their stretch run with linebackers Matt Milano and Tyrel Dodson designated to return to practice after spending time on injured reserve. Buffalo also signed receiver Jake Kumerow off its practice squad, adding depth at the position with starter John Brown placed on IR due to an ankle injury last weekend.

The Detroit Lions put cornerback Desmond Trufant and defensive tackle Danny Shelton on injured reserve. The Lions also activated tight end Hunter Bryant from IR and signed defensive tackle Kevin Strong to the active roster from the practice squad and signed cornerback Alex Myres to the practice squad. Defensive end Julian Okwara and cornerback Darryl Roberts returned to practice from IR today. Detroit plays at Chicago this weekend in its first game since coach Matt Patricia was fired.

Anthony Lynn and the Los Angeles Chargers has publicly acknowledged it would take a miracle for his team to make the playoffs even if the Chargers win their final five games to finish 8-8. The Chargers go into Sundays game against New England four games behind Miami and Indianapolis for the final AFC spots.

Harvey Langi is thriving while starting at inside linebacker for the New York Jets. He has 29 tackles since moving into the lineup in Week 9 following the trade of Avery Williamson to Pittsburgh. Langi has become a fan favorite with the Jets for his high energy approach on defense.

A 12th former NFL player has pleaded guilty in Kentucky in a multimillion-dollar health-fraud scheme. Former Washington Football Team and San Francisco 49ers cornerback Carlos Rogers pleaded guilty Monday to one charge of conspiring to defraud a program set up to reimburse former players for out-of-pocket medical expenses.

COLLEGE BASKETBALL-SCHEDULE

Coleman, No. 17 Texas beat No. 14 UNC 69-67 for Maui title

ASHEVILLE, N.C. (AP) Matt Coleman III hit a stepback jumper with 0.1 seconds left to help No. 17 Texas beat No. 14 North Carolina 69-67 for the championship of the relocated Maui Invitational. Coleman finished with 22 points and was the tournaments most valuable player for the Longhorns. Texas won despite blowing a 16-point first-half lead and falling behind in the final 2 1/2 minutes. Garrison Brooks had 18 points to lead the Tar Heels despite playing through an ankle injury that had him spend time in the locker room at least twice.

VIRUS OUTBREAK-COLLEGE SPORTS

Virus continues to scramble college sports schedules

UNDATED (AP) Michigan athletic director Warde Manuel is rebuking any suggestion the Wolverines would try to avoid facing rival Ohio State in the regular-season finale. He calls the notion ridiculous and infuriating. Michigans game against Maryland this weekend was canceled after the Wolverines suspended team activities because of an outbreak of COVID-19. It could also threaten their rivalry game against Ohio State on Dec. 12. A cancellation there could leave the Buckeyes with not enough games to be eligible for the Big Ten championship game.

In other virus-related college sports news:

The Las Vegas Bowl has been canceled because of the ongoing coronavirus pandemic. Executive director John Saccenti says it was a difficult decision but the right one considering the game was founded to help drive tourism to the gambling mecca. The decision comes as Nevada state officials ordered a statewide pause that includes smaller public and private gatherings. The game was slated to be the first bowl game played in Allegiant Stadium and was to feature a new matchup between the Pac-12 Conference and Southeastern Conference as part of a rotating cycle that also includes the Big Ten.

Mississippi has suspended team activities in football during the Rebels open date after COVID-19 test results came back. He says the team would wait on results from Wednesdays retesting. The Rebels are off this week after the SEC shuffled the schedule. They still have games to make up against Texas A&M and LSU.

Middle Tennessee has canceled Sundays home football game with UAB because of COVID-19, contact tracing and injuries inside the Blue Raiders program. Its the second straight week Middle Tennessee has canceled a game. Athletic director Chris Massaro says theyre down to 49 scholarship players and wouldve been forced to play some players coming off injuries.

Kent States football game at Miami of Ohio scheduled for Saturday has been canceled due to positive COVID-19 tests within the Golden Flashes program. The Mid-American Conference issued a statement saying the game has been declared a no contest. Its the second cancellation for Miami, which had its Nov. 17 game against Ohio wiped out.

George Mason has called off its mens basketball game at Maryland scheduled for Friday because of what the Virginia school says is a positive COVID-19 test during routine testing, which happens three times a week.

No. 17 Texas Tech has replaced a mens basketball game that was canceled because of COVID-19 concerns. The Red Raiders will now play Troy at home in a non-conference game Friday night.

No. 19 Richmonds mens basketball is pausing all activities and its game at College of Charleston on Wednesday night has been called off due to COVID-19 concerns within the Spiders program. Charleston said Tuesday it will look to reschedule with Richmond or find another opponent to make up the lost game.

College basketball is returning to Madison Square Garden this month for The Holiday Hoops Classic. In a matchup between the past two NCAA champions, Villanova and Virginia are scheduled to square off Dec. 19 in the heart of New York City. It will be the first college game at The Garden since the Big East Tournament was stopped at halftime of a March 12 quarterfinal between St. Johns and Creighton. Not long after that, the rest of the 2019-20 season was scuttled and the NCAA Tournament was canceled.

NBA SCHEDULE

Lakers-Clippers, Durant-Warriors set for NBA opening night

NEW YORK (AP) Kevin Durant is scheduled to make his Brooklyn debut against his former Golden State teammates before the Lakers begin their title defense in an all-Los Angeles matchup with the Clippers in the NBAs Dec. 22 opening-night doubleheader.

The Lakers will be back in action against the Dallas Mavericks on Dec. 25 as one of five games on the Christmas lineup.

The NBA announced the national TV schedule for the first three nights of the season on Wednesday. The complete schedule for the first half of the season, shortened to 72 games because of the coronavirus, will be announced Friday.

Elsewhere in the NBA:

LeBron James has agreed to a contract extension with the Los Angeles Lakers. James previous deal ran only through the upcoming season with a player option for 2021-22, allowing him to leave the NBA champions as a free agent next summer if he chose. Instead, the four-time NBA champion committed to play through his 20th NBA season with the Lakers, his third club after title-winning runs in Cleveland and Miami.

Zion Williamson expects to unleash a version of himself that is healthier, more demonstrative and less restrained in his second NBA season with the New Orleans Pelicans. Williamson says Year 1 was a lot mentally and physically for him. But he says he needed that experience. Williamson also says he was not able to showcase a lot of his game last season because he was more focused on fitting in with the team and trying not to be the rookie to mess up. Williamson says he now feels great physically and understands much more about playing in the NBA.

Boston Celtics point guard Kemba Walker says his left knee has responded well to a stem cell injection that is expected to keep him out until at least January. Walker says he wasnt himself during the playoffs, when the Celtics reached the Eastern Conference finals. He says he wont rush back to play until he is back at his best.

MLB-NEWS

Royals sign lefty starter Mike Minor to 2 year, $18M deal

UNDATED (AP) Left-hander Mike Minor and the Kansas City Royals have finalized an $18 million, two-year deal, reuniting the 32-year-old starter with the club that helped him revive his career.

The contract includes a club option for 2023 for $13 million with a $1 million buyout. The 32-year-old Minor split 2020 between the Texas Rangers and Oakland Athletics, going 1-6 with a 5.56 ERA and diminished velocity after posting the best numbers of his career a year earlier.

In other MLB news:

The Minnesota Twins have agreed to a $2.2 million, one-year contract with reliever Tyler Duffey, according to a person with knowledge of the deal. Duffey was one of seven Twins players eligible for salary arbitration for the 2021 season, joining left fielder Eddie Rosario, starting pitcher Jos Berros, center fielder Byron Buxton, closer Taylor Rogers, catcher Mitch Garver and relief pitcher Matt Wisler.

The Chicago White Sox have declined to offer 2021 contracts to right fielder Nomar Mazara and pitcher Carlos Rodn, sending the pair into free agency. Meanwhile, Jace Fry gets a one-year deal worth $862,500.

The most recent first-round draft pick of the Tampa Bay Rays has undergone surgery on his right shoulder. Pitcher Nick Bitsko had the operation Tuesday to repair a labrum issue. The 18-year-old from Pennsylvania has displayed a fastball that reached just under 100 mph. The Rays have not ruled out Bitsko being able to pitch at some point during the 2021 season.

The Milwaukee Brewers are taking a step to shore up their catching situation after getting little production from that position last season. A person familiar with the situation tells The Associated Press the Brewers have agreed to terms on a major league deal with Luke Maile. Maile was with the Pittsburgh Pirates last season but missed the entire abbreviated season due to a fractured right index finger.

The Chicago Cubs have claimed reliever Robert Stock off waivers from the Boston Red Sox. Stock appeared in 10 games with Boston during the pandemic-shortened season, going 0-1 with a 4.73 ERA. The 31-year-old right-hander was designated for assignment last week.

NHL-NEWS

Bettman: NHL players have to decide to pay now or later

UNDATED (AP) NHL Commissioner Gary Bettman says players are likely going to have to pay one way or another to make up for lost league revenue whenever the 2020-21 season gets underway. Bettman says the pandemic will affect revenue and that is expected to affect the 50-50 revenue-sharing split between owners and players.

Players will have to bear the brunt of any shortfall to owners. Bettman says the question is whether players should defer a higher percentage of their salaries now or face the potential of having the salary cap stay flat for several years.

OBIT-RAFER JOHNSON

Rafer Johnson, 1960 Olympic decathlon champion, dies at 86

LOS ANGELES (AP) Rafer Johnson, who won the decathlon at the 1960 Rome Olympics and helped subdue Robert F. Kennedys assassin in 1968, died Wednesday. He was 86.

He died at his home in the Sherman Oaks section of Los Angeles, according to family friend Michael Roth. No cause of death was announced.

Johnson was among the worlds greatest athletes from 1955 through his Olympic triumph in 1960, winning a national decathlon championship in 1956 and a silver medal at the Melbourne Olympics that same year.

On June 5, 1968, Johnson was working on Kennedys presidential campaign when the Democratic candidate was shot in the kitchen of the Ambassador Hotel in Los Angeles. Johnson joined former NFL star Rosey Grier and journalist George Plimpton in apprehending Sirhan Sirhan moments after he shot Kennedy, who died the next day.

More:
Update on the latest sports - Newscenter1.tv

Read More...

Update on the latest sports-UPDATED – Newscenter1.tv

Thursday, December 3rd, 2020

NFL-SCHEDULE

Steelers overcome rust, short-handed Ravens to move to 11-0

PITTSBURGH (AP) Ben Roethlisberger threw for 266 yards and a fourth-quarter touchdown to JuJu Smith-Schuster and the Steelers improved to 11-0 with a disjointed 19-14 win over the undermanned Baltimore Ravens.

The game was postponed three times while the Ravens dealt with a COVID-19 outbreak that forced Baltimore to take the field minus star quarterback Lamar Jackson among others.

The extended layoff led to some ugly football in a game filled with turnovers and inconsistent play. Still, the Steelers survived behind just enough offense and a defense that forced a pair of turnovers and had three sacks.

NFL-NEWS

Goodell: NFL committed to finishing regular season on time

UNDATED (AP) NFL Commissioner Roger Goodell says the league remains committed to finishing the regular season as scheduled. Goodell also said on a conference call that while the NFL is considering a bubble format for the playoffs, although it wouldnt necessarily resemble what the NHL and NBA used successfully in completing their seasons.

The leagues chief football administrative officer, stressed that the NFL plans to finish the schedule within the original 17-week format.

In other NFL news:

Quarterbacks Drew Lock and Brett Rypien (RIH-pihn) returned to the Denver Broncos practice Wednesday after coming off the reserve/COVID-19 list while the Broncos isolated practice squad veteran Blake Bortles. All three quarterbacks were banned from last weekends game against the New Orleans Saints after failing to wear their masks around quarterback Jeff Driskel, who tested positive for the coronavirus on Thanksgiving. The Broncos returned rookie receiver Kendall Hinton to their practice squad. Hinton filled in for Lock on Sunday when he completed just one of nine passes and was intercepted twice. Lock praised Hinton for his emergency QB work Sunday.

The Green Bay Packers have activated rookie linebacker Krys Barnes from the reserve/COVID-19 list. Barnes has missed three straight games since getting placed on that list Nov. 6. The undrafted free agent from UCLA has 48 tackles.

The Cleveland Browns are dealing with another COVID-19 case after an unidentified staff member tested positive. The team closed its facility Wednesday to conduct contact tracing, which has become routine the past two weeks because of several other positive tests. The Browns are expected to practice indoors after heavy snow in the Cleveland area. They activated star defensive end Myles Garrett from the reserve/COVID-19 list on Tuesday and expect him to practice as they get ready to play at Tennessee on Sunday. Garrett missed two games after becoming infected.

Quarterback Mike Glennon is getting another start for the Jacksonville Jaguars even though Gardner Minshew is healthy. Coach Doug Marrone says Minshew has been cleared to practice in full after recovering from a sprained thumb on his throwing hand, but hes sticking with Glennon at Minnesota on Sunday. Glennon was solid in his first start since Week 4 of the 2017 season.

The Buffalo Bills are in position to get healthier for their stretch run with linebackers Matt Milano and Tyrel Dodson designated to return to practice after spending time on injured reserve. Buffalo also signed receiver Jake Kumerow off its practice squad, adding depth at the position with starter John Brown placed on IR due to an ankle injury last weekend.

The Detroit Lions put cornerback Desmond Trufant and defensive tackle Danny Shelton on injured reserve. The Lions also activated tight end Hunter Bryant from IR and signed defensive tackle Kevin Strong to the active roster from the practice squad and signed cornerback Alex Myres to the practice squad. Defensive end Julian Okwara and cornerback Darryl Roberts returned to practice from IR today. Detroit plays at Chicago this weekend in its first game since coach Matt Patricia was fired.

Anthony Lynn and the Los Angeles Chargers has publicly acknowledged it would take a miracle for his team to make the playoffs even if the Chargers win their final five games to finish 8-8. The Chargers go into Sundays game against New England four games behind Miami and Indianapolis for the final AFC spots.

Harvey Langi is thriving while starting at inside linebacker for the New York Jets. He has 29 tackles since moving into the lineup in Week 9 following the trade of Avery Williamson to Pittsburgh. Langi has become a fan favorite with the Jets for his high energy approach on defense.

A 12th former NFL player has pleaded guilty in Kentucky in a multimillion-dollar health-fraud scheme. Former Washington Football Team and San Francisco 49ers cornerback Carlos Rogers pleaded guilty Monday to one charge of conspiring to defraud a program set up to reimburse former players for out-of-pocket medical expenses.

COLLEGE BASKETBALL-SCHEDULE

Coleman, No. 17 Texas beat No. 14 UNC 69-67 for Maui title

ASHEVILLE, N.C. (AP) Matt Coleman III hit a stepback jumper with 0.1 seconds left to help No. 17 Texas beat No. 14 North Carolina 69-67 for the championship of the relocated Maui Invitational. Coleman finished with 22 points and was the tournaments most valuable player for the Longhorns. Texas won despite blowing a 16-point first-half lead and falling behind in the final 2 1/2 minutes. Garrison Brooks had 18 points to lead the Tar Heels despite playing through an ankle injury that had him spend time in the locker room at least twice.

VIRUS OUTBREAK-COLLEGE SPORTS

Virus continues to scramble college sports schedules

UNDATED (AP) Michigan athletic director Warde Manuel is rebuking any suggestion the Wolverines would try to avoid facing rival Ohio State in the regular-season finale. He calls the notion ridiculous and infuriating. Michigans game against Maryland this weekend was canceled after the Wolverines suspended team activities because of an outbreak of COVID-19. It could also threaten their rivalry game against Ohio State on Dec. 12. A cancellation there could leave the Buckeyes with not enough games to be eligible for the Big Ten championship game.

In other virus-related college sports news:

The Las Vegas Bowl has been canceled because of the ongoing coronavirus pandemic. Executive director John Saccenti says it was a difficult decision but the right one considering the game was founded to help drive tourism to the gambling mecca. The decision comes as Nevada state officials ordered a statewide pause that includes smaller public and private gatherings. The game was slated to be the first bowl game played in Allegiant Stadium and was to feature a new matchup between the Pac-12 Conference and Southeastern Conference as part of a rotating cycle that also includes the Big Ten.

Mississippi has suspended team activities in football during the Rebels open date after COVID-19 test results came back. He says the team would wait on results from Wednesdays retesting. The Rebels are off this week after the SEC shuffled the schedule. They still have games to make up against Texas A&M and LSU.

Middle Tennessee has canceled Sundays home football game with UAB because of COVID-19, contact tracing and injuries inside the Blue Raiders program. Its the second straight week Middle Tennessee has canceled a game. Athletic director Chris Massaro says theyre down to 49 scholarship players and wouldve been forced to play some players coming off injuries.

Kent States football game at Miami of Ohio scheduled for Saturday has been canceled due to positive COVID-19 tests within the Golden Flashes program. The Mid-American Conference issued a statement saying the game has been declared a no contest. Its the second cancellation for Miami, which had its Nov. 17 game against Ohio wiped out.

George Mason has called off its mens basketball game at Maryland scheduled for Friday because of what the Virginia school says is a positive COVID-19 test during routine testing, which happens three times a week.

No. 17 Texas Tech has replaced a mens basketball game that was canceled because of COVID-19 concerns. The Red Raiders will now play Troy at home in a non-conference game Friday night.

No. 19 Richmonds mens basketball is pausing all activities and its game at College of Charleston on Wednesday night has been called off due to COVID-19 concerns within the Spiders program. Charleston said Tuesday it will look to reschedule with Richmond or find another opponent to make up the lost game.

College basketball is returning to Madison Square Garden this month for The Holiday Hoops Classic. In a matchup between the past two NCAA champions, Villanova and Virginia are scheduled to square off Dec. 19 in the heart of New York City. It will be the first college game at The Garden since the Big East Tournament was stopped at halftime of a March 12 quarterfinal between St. Johns and Creighton. Not long after that, the rest of the 2019-20 season was scuttled and the NCAA Tournament was canceled.

NBA SCHEDULE

Lakers-Clippers, Durant-Warriors set for NBA opening night

NEW YORK (AP) Kevin Durant is scheduled to make his Brooklyn debut against his former Golden State teammates before the Lakers begin their title defense in an all-Los Angeles matchup with the Clippers in the NBAs Dec. 22 opening-night doubleheader.

The Lakers will be back in action against the Dallas Mavericks on Dec. 25 as one of five games on the Christmas lineup.

The NBA announced the national TV schedule for the first three nights of the season on Wednesday. The complete schedule for the first half of the season, shortened to 72 games because of the coronavirus, will be announced Friday.

Elsewhere in the NBA:

LeBron James has agreed to a contract extension with the Los Angeles Lakers. James previous deal ran only through the upcoming season with a player option for 2021-22, allowing him to leave the NBA champions as a free agent next summer if he chose. Instead, the four-time NBA champion committed to play through his 20th NBA season with the Lakers, his third club after title-winning runs in Cleveland and Miami.

Zion Williamson expects to unleash a version of himself that is healthier, more demonstrative and less restrained in his second NBA season with the New Orleans Pelicans. Williamson says Year 1 was a lot mentally and physically for him. But he says he needed that experience. Williamson also says he was not able to showcase a lot of his game last season because he was more focused on fitting in with the team and trying not to be the rookie to mess up. Williamson says he now feels great physically and understands much more about playing in the NBA.

Boston Celtics point guard Kemba Walker says his left knee has responded well to a stem cell injection that is expected to keep him out until at least January. Walker says he wasnt himself during the playoffs, when the Celtics reached the Eastern Conference finals. He says he wont rush back to play until he is back at his best.

MLB-NEWS

Royals sign lefty starter Mike Minor to 2 year, $18M deal

UNDATED (AP) Left-hander Mike Minor and the Kansas City Royals have finalized an $18 million, two-year deal, reuniting the 32-year-old starter with the club that helped him revive his career.

The contract includes a club option for 2023 for $13 million with a $1 million buyout. The 32-year-old Minor split 2020 between the Texas Rangers and Oakland Athletics, going 1-6 with a 5.56 ERA and diminished velocity after posting the best numbers of his career a year earlier.

In other MLB news:

The Minnesota Twins have agreed to a $2.2 million, one-year contract with reliever Tyler Duffey, according to a person with knowledge of the deal. Duffey was one of seven Twins players eligible for salary arbitration for the 2021 season, joining left fielder Eddie Rosario, starting pitcher Jos Berros, center fielder Byron Buxton, closer Taylor Rogers, catcher Mitch Garver and relief pitcher Matt Wisler.

The Chicago White Sox have declined to offer 2021 contracts to right fielder Nomar Mazara and pitcher Carlos Rodn, sending the pair into free agency. Meanwhile, Jace Fry gets a one-year deal worth $862,500.

The most recent first-round draft pick of the Tampa Bay Rays has undergone surgery on his right shoulder. Pitcher Nick Bitsko had the operation Tuesday to repair a labrum issue. The 18-year-old from Pennsylvania has displayed a fastball that reached just under 100 mph. The Rays have not ruled out Bitsko being able to pitch at some point during the 2021 season.

The Milwaukee Brewers are taking a step to shore up their catching situation after getting little production from that position last season. A person familiar with the situation tells The Associated Press the Brewers have agreed to terms on a major league deal with Luke Maile. Maile was with the Pittsburgh Pirates last season but missed the entire abbreviated season due to a fractured right index finger.

The Chicago Cubs have claimed reliever Robert Stock off waivers from the Boston Red Sox. Stock appeared in 10 games with Boston during the pandemic-shortened season, going 0-1 with a 4.73 ERA. The 31-year-old right-hander was designated for assignment last week.

NHL-NEWS

Bettman: NHL players have to decide to pay now or later

UNDATED (AP) NHL Commissioner Gary Bettman says players are likely going to have to pay one way or another to make up for lost league revenue whenever the 2020-21 season gets underway. Bettman says the pandemic will affect revenue and that is expected to affect the 50-50 revenue-sharing split between owners and players.

Players will have to bear the brunt of any shortfall to owners. Bettman says the question is whether players should defer a higher percentage of their salaries now or face the potential of having the salary cap stay flat for several years.

OBIT-RAFER JOHNSON

Rafer Johnson, 1960 Olympic decathlon champion, dies at 86

LOS ANGELES (AP) Rafer Johnson, who won the decathlon at the 1960 Rome Olympics and helped subdue Robert F. Kennedys assassin in 1968, died Wednesday. He was 86.

He died at his home in the Sherman Oaks section of Los Angeles, according to family friend Michael Roth. No cause of death was announced.

Johnson was among the worlds greatest athletes from 1955 through his Olympic triumph in 1960, winning a national decathlon championship in 1956 and a silver medal at the Melbourne Olympics that same year.

On June 5, 1968, Johnson was working on Kennedys presidential campaign when the Democratic candidate was shot in the kitchen of the Ambassador Hotel in Los Angeles. Johnson joined former NFL star Rosey Grier and journalist George Plimpton in apprehending Sirhan Sirhan moments after he shot Kennedy, who died the next day.

The rest is here:
Update on the latest sports-UPDATED - Newscenter1.tv

Read More...

Stem Cell Tourism: Providing Hope For Treatment Away From …

Tuesday, November 10th, 2020

The promise of treatment or cure of many chronic illnesses has led to thousands of patients worldwide travelling internationally to receive Stem Cell Treatment. This is what has come to be known as stem cell tourism.

The medical facilities offer Stem Cell Treatment to treat conditions like Spinal Cord Injury, Alzheimers and Parkinsons by introducing stem cells into the patients bodies. The stem cells would then develop into new tissue or cells and repair damage caused by illness or injury.

Such clinics are mainly spread across Asia, Eastern Europe and South America. Patients from the West the United States, Western Europe and Australia travel to these facilities to receive treatment. The main reason for this travel is that the approval of drugs in the East is faster and more accommodative than in western countries.

One of the Bloomberg Businessweek publications told the story of an American man who travelled to China to receive treatment for paralysis caused by severe Spinal Cord Injury.

24-year-old Chuck Melton suffered a head injury and a severe spinal cord injury after a diving accident. He remained paralysed from the chest down for five years with no hope for a cure in the US. He then opted to travel to China to receive Stem Cell Treatment.

He was injected with stem cells into his spine and was showing significant improvement a week later. His doctors noted that the involuntary muscle spasms in his legs had stopped. He was also able to perspire for the first time since the injury. This allowed him to spend time outdoors without endangering his life.

Five years after the treatment, he may not be able to walk but his quality of life has improved greatly. Before the procedure, Melton has told the media that he hoped to walk again but would be satisfied with any improvement in his condition.

Many conventional researchers may fault the treatment options offered by Stem Cell Treatment facilities in the East for lack of orderly research but for the patient whose time is limited, it is their only hope. With success stories such as Meltons, stem cell researchers are willing and have come out to defend their work.

The researchers have unequivocally stated that conventional medicine is not the only way to treat patients. It was noted that even some crucial treatment procedures in modern medicine bypassed the customary approval route. One such procedure is heart transplantation, it was quickly co-opted by heart surgeons worldwide (before orderly research) after Dr. Christiaan Barnards first successful procedure.

H/T:Stem Cell Tourism

Read more:
Stem Cell Tourism: Providing Hope For Treatment Away From ...

Read More...

Medical Tourism – Stem Cells Transplant Institute

Tuesday, November 10th, 2020

Stem cell therapy has the potential to improve the quality of life for many patients with chronic diseases such as; diabetes, Parkinsons disease, Alzheimers disease, rheumatoid arthritis and many other inflammatory diseases. Esthetic treatments like anti-aging options, weigh-loss, and hormone treatments are also showing great potential in the wellness/medical tourism field in Costa Rica.

McKinsey and Company, an influential global consulting company, reported that medical tourists from the United States and Canada, prefer Latin American countries including Costa Rica because of the short travel time, affordable costs, and the opportunity to enjoy a memorable vacation.

There are direct flights from many cities in the United States and Europe; it is only a 2.5-hour flight from Miami, Florida to San Jose, Costa Rica or a 3.5-hour flight from Houston, Texas. TheStem Cells Transplant Instituteis located close to the airport in Escazu, San Jose.

Treatment packages include a two-night stay at the beautifulIntercontinental Hotellocated just minutes from the clinic as well as shopping and restaurants. Another option for accommodations for patients to stay in would be theHotel Quality Real San Jos. From either location, you could enjoy the rich culture and heritage of San Jose by taking a VIP bus tour or, if you are feeling a bit more adventurous, venture out on your own to Avenida Central and visit the many museums, parks, shops and restaurants located along the avenue.

Traveling to Costa Rica for a stem cell treatment allows you the opportunity to explore a beautiful and diverse country. Approximately 2 million tourists come to explore the beauty of Costa Rica every year; they come to hike the rainforests, lounge on thebeachor relax in the hot springs. Costa Rica is also a bird watching paradise with more than 850 species, more species than the United States and Canada combined. However, if you are just looking to relax, the country also has some amazing spas located in the city or surrounded by the beauty and solitude of the rain forest. Many resorts specialize inyoga and wellness retreats, spas, and weight-loss programs. The Nicoya Peninsula around Tambor, Montezum and Mal Pais is largely undeveloped and a great place to go on some nature tours. For an ICT approved, excellent travel agency, for complete travel packages, contactCosta Rican Trails. Go to https://bancoinfo.co.cr for all bank locations and hours.

Read this article:
Medical Tourism - Stem Cells Transplant Institute

Read More...

Anti-Aging Market Research Report: By Product, Treatment, Demography – Global Industry Analysis and Growth Forecast to 2030 – PRNewswire

Tuesday, November 10th, 2020

NEW YORK, Nov. 4, 2020 /PRNewswire/ --

Anti-Aging Market Research Report: By Product (Anti-Wrinkle, Hair Color, Ultraviolet Absorption, Anti-Stretch Mark), Treatment (Hair Restoration, Anti-Pigmentation, Adult Acne Therapy, Breast Augmentation, Liposuction, Chemical Peel), Demography (Generation X, Baby Boomers, Generation Y) - Global Industry Analysis and Growth Forecast to 2030

Read the full report: https://www.reportlinker.com/p05982459/?utm_source=PRN

The major driving factors for the anti-aging market are the rising number of awareness-raising seminars and conferences, surging geriatric population, increasing disposable income, technological advancements, expanding medical tourism sector, and escalating cosmetic surgery volume. These factors will lead to an increase in the industry revenue from $191.5 billion in 2019 to $421.4 billion in 2030, at an 8.1% CAGR during 20202030 (forecast period). Products used to diminish the signs of aging are easily available at physical stores and online portals.

A key factor aiding the anti-aging market advance is the rising number of seminars and conferences being organized to make plastic surgeons, students, and the general public about the advanced anti-aging treatments. For instance, the Aesthetic & Anti-Aging Medicine World Congress (AMWC) hosted by EuroMediCom (Informa Group) in April 2019 in Monte Carlo, Monaco, included five knowledge sharing and discussion sessions on anti-aging and aesthetics. Formerly, the Aesthetic & Anti-Aging Medicine World Congress 13th Edition was hosted in Thailand in September 2018 by the American Academy of Anti-Aging Medicine (A4M).

Another major reason the demand for anti-aging treatments and products is increasing is the booming geriatric population. The United Nations says that the number of people in the age group of 65 and above will surge from 703 million in 2019 to 1.5 billion by 2050. With age, people experience stem cell and fibrous tissue loss, which leads to dryness, wrinkles, sagging, and pigmentary alteration. Therefore, in order to continue looking young and attractive, the geriatric population regularly uses anti-aging remedies, which tighten and revitalize the skin, in addition to making people look young.

North America is the dominant region in the anti-aging market currently, owing to the rising plastic surgery volume and geriatric population. The UN expects the number of elderly people on the continent to increase to 96.2 million by 2050 from 59.9 million in 2019. This, coupled with the growing volume of plastic surgeries, is expected to result in a massive surge in the demand for various therapies and products that help people look young and aesthetically appealing.

Hence, as more people age and their awareness regarding how they can reverse or physically hide the effects of this process rises, the market will keep blossoming.

Read the full report: https://www.reportlinker.com/p05982459/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read the original post:
Anti-Aging Market Research Report: By Product, Treatment, Demography - Global Industry Analysis and Growth Forecast to 2030 - PRNewswire

Read More...

Regenerative Medicine Market 2020: Analysis, Top Companies, Size, Share, Demand and Opportunity To 2025 – Eurowire

Tuesday, November 10th, 2020

According to IMARC Groups latest report, titled Regenerative Medicine Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025,. Looking forward, IMARC Group expects the global regenerative medicine market to continue its strong growth during the next five years.

Regenerative medicine refers to a field of biomedical sciences involved in restoring the structure and function of damaged cells, organs, and tissues. It includes the study of stem cells that are developed in laboratories and then safely inserted into the human body to regenerate damaged bones, cartilage, blood vessels, and organs. Cellular and acellular regenerative medicines are widely adopted in various clinical therapeutic procedures, including cell therapies, immunomodulation, and tissue engineering. They have the potential to treat various chronic diseases, including Alzheimers, Parkinsons, cardiovascular disorders (CVDs), osteoporosis, spinal cord injuries, etc.

Request for a free sample copy of this report: https://www.imarcgroup.com/regenerative-medicine-market/requestsample

Market Trends

The rising prevalence of chronic diseases and genetic disorders is primarily driving the demand for regenerative medicine across the globe. Moreover, the growing geriatric population who are more prone to musculoskeletal, dermatological, and cardiological disorders is also augmenting the need for regenerative medicines. Furthermore, several technological advancements in cell-based therapies have led to the adoption of 3D bioprinting techniques and artificial intelligence (AI), thereby further propelling the market for regenerative medicine. Moreover, regenerative medicine decreases the risk of organ rejection by the body post-transplant and increases the patients recovery speed, thereby gaining traction in numerous organ transplantation procedures. The increasing investments in extensive R&D activities in the field of medical sciences are expected to drive the market for regenerative medicine.

Regenerative Medicine Market 2020-2025 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

The report has segmented the market on the basis of type, application, end user and region.

Breakup by Type:

Breakup by Application:

Breakup by End User:

Ask Analyst for Instant Discount and Download Full Report with TOC & List of Figure: https://bit.ly/2RAf08Y

Breakup by Region:

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US:IMARC Group30 N Gould St, Ste RSheridan, WY 82801, USAWebsite: https://www.imarcgroup.com/Email: [emailprotected]USA: +1-631-791-1145Follow us on twitter: @imarcglobalLinkedin: https://www.linkedin.com/company/imarc-group

Originally posted here:
Regenerative Medicine Market 2020: Analysis, Top Companies, Size, Share, Demand and Opportunity To 2025 - Eurowire

Read More...

Prop. 14: In the COVID age, can California still afford its stem cell research program? – CALmatters

Thursday, October 15th, 2020

In summary

Proposition 14 asks voters to spend nearly $8 billion to continue the stem cell research program at a time when the coronavirus pandemic has decimated the state budget.

For the second time in 16 years, California voters will decide the fate of the states multi-billion dollar stem cell research program that established the state as a worldwide leader.

How the times have changed.

In November, as the pandemic drags on, Proposition 14 asks voters to spend nearly $8 billion to continue the program during a period when the research environment has significantly evolved and coronavirus has battered the states budget.

The bond measure would approve $5.5 billion in bonds to keep the states stem cell research agency running and grants flowing to California universities and companies.

At least $1.5 billion would be earmarked for brain and central nervous system diseases like Alzheimers and Parkinsons. The overall cost of the bonds and their interest totals about $7.8 billion, according to the state legislative analyst. The state would pay about $260 million annually for 30 years, or about 1 percent of Californias annual budget.

Proposition 14 is essentially a repeat with a bigger price tag and a few tweaks of Proposition 71, which California voters approved in 2004 after then-President George W. Bush prohibited, on religious grounds, all federal funding of any stem cell research using human embryos.

The bond measure would approve $5.5 billion in bonds to keep the states stem cell research agency running and grants flowing to California universities and companies.

That groundbreaking measure authorized $3 billion in state bonds to create the states stem cell research agency, the California Institute for Regenerative Medicine, and fund grants for research into treatments for Alzheimers disease, cancer, spinal cord injuries and other diseases.

The institute has nearly used up its original funding, so Prop. 71s author, real estate investor and attorney Robert N. Klein II, led a new effort to get Prop. 14 on the November ballot.

This time, embryonic stem cell research is in a much different place, with federal funding no longer blocked and more funding from the biotech industry.

Voters will want to consider what Californias previous investment in stem cell research has accomplished. Its a nuanced track record.

While many scientific experts agree that Prop 71 was a bold social innovation that successfully bolstered emerging stem cell research, some critics argue that the institutes grantmaking was plagued by conflicts of interest and did not live up to the promises of miracle cures that Prop. 71s supporters made years ago. Although the agency is funded with state money, its overseen by its own board and not by the California governor or lawmakers.

The agency had done a very good job of setting priorities for stem cell research, including research using human embryos, and doling out $300 million annually to build up California as a regenerative medicine powerhouse, according to a 2013 evaluation by the National Academies of Science, Engineering and Medicine.

But the report also found that because the institutes board is made up of scientists from universities and biotech firms likely to apply for grants, board members had almost unavoidable conflicts of interest.

Because human stem cells can develop into many types of cells, including blood, brain, nerve and muscle cells, scientists have long looked to them for potential treatments for currently incurable diseases and injuries. Researchers use two types of stem cells: embryonic stem cells, derived from unused human embryos created through in vitro fertilization, and adult stem cells, which are harder to work with but in some cases can be coaxed in a lab into behaving more like embryonic stem cells.

From the start, stem cell research has been ethically charged and politically controversial because human embryos are destroyed in some types of studies. Federal restrictions on the research have waxed and waned, depending on which political party holds power. While former President Bush restricted federal money for embryonic stem cell research, former President Obama removed those restrictions.

The Trump administration has restricted government research involving fetal tissue but not embryonic stem cells. However, anti-abortion lawmakers have called on the President to once again end federal funding for embryonic stem cell research.

California-funded research has led to one stem cell treatment for a form of Severe Combined Immunodeficiency known as the bubble baby disease. Children with the rare disease dont make enough of a key enzyme needed for a normal immune system. Without treatment, they can die from the disease if not kept in a protective environment. The U.S. Food and Drug Administration is now reviewing the treatment but has not yet approved it for widespread use.

Although many of the agencys early grants were for basic science, the institute also has supported 64 clinical trials of treatments for many types of cancer, sickle cell disease, spinal cord injuries, diabetes, kidney disease and amyotrophic lateral sclerosis, commonlyknown as Lou Gehrigs disease.

A June 2020 analysis by University of Southern California health policy researchers estimated that taxpayers initial $3 billion investment in the research institute helped create more than 50,000 jobs and generated $10 billion for the states economy.

Gov. Gavin Newsom has endorsed Proposition 14, and other supporters include the Regents of the University of California, the California Democratic Party, the Juvenile Diabetes Research Foundation, patient advocacy groups like the March of Dimes, and some local politicians and chambers of commerce.

Supporters have raised more than $8.5 million, including about $2 million from billionaire Dagmar Dolby, to pass the measure, according to California Secretary of State campaign finance reports.

The passage of Proposition 71 helped save my life, Sandra Dillon, a blood cancer patient, wrote in a San Diego Union-Tribune commentary supporting Proposition 14. She wrote that she had benefited from a drug developed with Institute-funded research that has been designated by the FDA as a breakthrough therapy.

It is unimaginable to think that Californians would vote to discontinue this amazing effort I dont know where I would be or what condition I would be in if it wasnt for the investment Californians made nearly two decades ago.

I think the agencys done good work, but this was never planned to be funded forever with debt.

Lawrence Goldstein, a UC San Diego professor of cellular and molecular medicine and stem cell researcher, said the grants were instrumental in furthering his research on treatments for Alzheimers disease and that Prop. 14 will help create new jobs. The agency has funded a great deal of very important stem cell medical research thats already produced terrific results and has the prospect of saving many more lives in the decade to come, he said.

Opponents include one member of the institutes board and a nonprofit that advocates for privacy in genetic research. They contend that the proposition seeks too much money and does not sufficiently address the conflicts of interest that cropped up after Prop. 71 was passed. They also note that private funding, including venture capital, for stem cell research has grown in recent years. Opponents had raised only $250 by late September, from a single contribution by the California Pro Life Council.

The editorial boards of some of Californias biggest newspapers also have opposed the measure, including the Los Angeles Times, the Orange County Register, the San Francisco Chronicle and the San Jose Mercury News/East Bay Times. The Fresno Bee, Modesto Bee, and San Luis Obispo Tribune newspaper editorial boards support Prop 14.

Jeff Sheehy, the only institute board member not to support Proposition 14, told CalMatters that the research environment has changed since voters initially approved state funding for stem cell research in 2004 and that California should prioritize other needs like education, health care, and housing.

I think the agencys done good work, but this was never planned to be funded forever with debt, Sheehy said. At this point the state cant afford it; were looking at a huge deficit.

Read the original here:
Prop. 14: In the COVID age, can California still afford its stem cell research program? - CALmatters

Read More...

Stem Cell Research on the Ballot: A Closer Look at Prop 14 – Fullerton Observer

Thursday, October 15th, 2020

Californians are voting on a number of propositions that deal with a wide variety of issues this election season. Heres a closer look at Proposition 14, which deals with stem cell research. This is a summary of information taken from the official California voters guide and the website Ballotpedia.

Prop 14: Authorizes Bonds Continuing Stem Cell Research. Initiative Statute.

This ballot initiative would issue $5.5 billion in general obligation bonds for the California Institute for Regenerative Medicine (CIRM), which was created to fund stem cell research. In 2004, voters approved Proposition 71, which created CIRM, issued $3.00 billion in bonds to finance CIRM, and established a State constitutional right to conduct stem cell research.

As of October 2019, CIRM had $132 million in funds remaining. On July 1, 2019, CIRM suspended applications for new projects due to depleted funds.

This ballot initiative would require CIRM to spend no more than 7.5% of the bond funds on operation costs. The remaining bond funds would be spent on grants to entities that conduct research, trials, and programs related to stem cells, as well as start-up costs for facilities.

Dedicates $1.5 billion to research and therapy for Alzheimers, Parkinsons, stroke, epilepsy, and other brain and central nervous system diseases and conditions.

An Independent Citizens Oversight Committee (ICOC) is responsible for governing CIRM.

Arguments in Favor

Nearly half of all California families include a child or adult with medical conditions who could benefit from stem cell research, treatments, and cures.

Prop 14 provides continued funding to develop treatments, advance clinical trials, and achieve new scientific breakthroughs for Californias patients with Cancer, Diabetes, Heart Disease, Alzheimers, Parkinsons, HIV/AIDS, ALS, MS, Sickle Cell Disease, Lung Diseases, Kidney Disease, Bubble Baby Disease, Age-Related Blindness and Genetic Blindness, Epilepsy, Stroke, Schizophrenia, Autism, other Mental Health and Brain Conditions, and Infectious Diseases like COVID-19.

Californias original stem cell funding, which runs out this year, has already led to significant progress in the development of treatments and cures, including 92 FDA-approved clinical trials for chronic disease and injuries, over 2,900 medical discoveries, and demonstrated benefits for patients and research on chronic diseases including Cancer, Diabetes, Heart Conditions, Blindness, HIV/AIDS, ALS, Children with Immune Deficiencies, Paralysis, and Kidney Disease.

New revenues, economic activity and jobs are generated by this funding that will contribute to Californias economic recovery.

Chronic diseases, conditions and injuries are cutting lives short and costing Californians billions in healthcare costs. We must continue our investment, developing stem cell treatments to improve the health and reduce the suffering of millions of Californians.

Arguments Against

We cant afford to waste billions. In the middle of an economic crisis, with soaring unemployment and budget shortfalls in the tens of billions of dollars, we dont have money to burn.

And thats on top of the nearly $3 billion this troubled State agency has spent over the past 15 yearswith poor results. After an extensive analysis of spending by the State agency handing out billions in grants, the San Francisco Chronicle concluded that, The predicted financial windfall has not materialized. Only a few federally approved therapies have resulted.

Prop 14 funds a bureaucracy with serious problems. Some have questioned the integrity and independence of the State agency overseeing these funds.

Others can do this job better. The National Institute of Health provides $1.5 billion a year in grants to fund the same type of research. Private investors and companies, including many in California, have made great strides in using stem cells to cure diseasesusing private funds, not tax dollars.

Paying back Prop 14s costs of $7.8 billion could mean huge tax increases at a time when our economy is on its knees. Or laying off thousands of nurses and other heroes who do the real work of keeping California healthy.

Groups supporting Prop 14 include:

California Democratic Party

JDRF (Juvenile Diabetes Research Foundation)

University of California Board of Regents

Top donors to Yes on 14:

Robert N. Klein II ($3,625,000)

Dagmar Dolby ($2,059,000)

Juvenile Diabetes Research Foundation ($1,750,000)

Open Philanthropy Action Fund ($580,000)

Ann S. Tsukamoto ($500,000)

Groups opposed to Prop 14 include:

Editorial boards of The Orange County Register, The Bakersfield Californian, Mercury News & East Bay Times, San Francisco Chronicle, and Los Angeles Times

Top donors to No on 14:

None reported

Protect local journalism please subscribe to the print edition of the Fullerton Observer. Our online edition is free, but we depend on print subscriptions from readers. Annual subscription is only $35/year.It only takes a minute Click Here To Subscribe. Thank you for your support for the Fullerton Observer. Click here to view a copy of the print edition.

Read more:
Stem Cell Research on the Ballot: A Closer Look at Prop 14 - Fullerton Observer

Read More...

Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue…

Thursday, October 15th, 2020

SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has entered into an exclusive license agreement with Personalized Stem Cells, Inc. (PSC) to acquire global rights to its adipose derived mesenchymal stem cells (MSCs) for patients suffering from acute respiratory distress syndrome (ARDS) associated with COVID-19, which have been cleared for a Phase 1 clinical trial by the FDA.

The study is a single arm, non-randomized Phase 1 study of the safety and preliminary efficacy of an adipose-derived allogeneic MSC product candidate. The outcome data will be compared to contemporaneous non-enrolled patients at the same clinical site(s) as the enrolled patients. The primary objective is to evaluate the safety of intravenous infusion of allogeneic adipose stem cells in patients with COVID-19 and in respiratory distress. The secondary objective is to evaluate a set of safety and efficacy outcome variables to give guidance regarding the risk/benefit ratio in patients with COVID-19 respiratory distress.

More information on the Phase 1 trial can be found at:

https://clinicaltrials.gov/ct2/show/NCT04486001?term=coronastem&draw=2&rank=1

Sorrento will be assuming responsibility for executing the Phase 1 trial, which is targeted to enroll about 20 hospitalized COVID-19 patients in California. Pending the results of the Phase 1 trial, Sorrento expects to expand into Phase 2 trials in multiple relevant geographies as may be determined in consultation with applicable regulatory authorities.

Stem cells have been demonstrated to support resolution of symptoms in multiple disease settings and have the potential to reduce the long-term effects associated with pulmonary tissue damage for these patients. More information on the potential use and benefits of MSCs for patients with COVID-19 can be found in the recently published review at:

https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02380-2

Stem cells represent a treatment modality with high potential to help in the fight against COVID-19 as a stand-alone therapy or in synergy with other product candidates in Sorrentos pipeline, including small molecules (abivertinib or salicyn-30) and neutralizing antibodies (STI-1499 or STI 2020).

Until a time where early treatments are more readily available, it is important to provide patients severely afflicted with COVID-19 multimodal solutions that can help increase survival, reduce the time spent in the hospital and reduce long-term sequelae. The long-term lingering effects of COVID-19 on the body can persist for months after patients leave the hospital, especially for patients that received ventilator support. Shortness of breath, difficulty doing simple tasks and pulmonary fibrosis are among the common complaints of long-term effects of the disease on COVID-19 patients leaving the ICU.

Dr. Robert Harman, CEO of PSC stated, We are delighted to be working with a company such as Sorrento, that has the vision and expertise to take our program through the next steps in the clinical development process. Sorrento saw the translational value of our decades of work in animal health and has acknowledged the extensive manufacturing and regulatory work we have done in bringing human cell lines to a Phase 1 FDA clearance. We are looking forward to collaborating on this initiative and beyond.

Dr. Henry Ji, Chairman and CEO of Sorrento stated, Stem cells were a missing piece in our comprehensive portfolio of potential solutions against COVID-19. We now cover multiple stages of the continuum of care from prevention to potential therapeutic solutions for the most advanced stages of the disease. With PSCs Phase 1 product candidate, we hope to move quickly through the next clinical trials, and, if successful, be able to provide a supportive therapy that may save the lives of the most advanced patients and may also ensure patients who have to undergo intensive care can benefit from a therapy with the potential to minimize the long-term effects of the disease due to the lung damage created by the virus early in the infection.

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrentos multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs), and clinical stage oncolytic virus (Seprehvir, Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP, ACE-MAB, COVI-MAB, COVI-GUARD, COVI-SHIELD, COVI-AMG and T-VIVA-19; and diagnostic test solutions, including COVI-TRACK, COVI-STIX and COVI-TRACE.

Sorrentos commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (RTX), and ZTlido (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido was approved by the FDA on February 28, 2018.

For more information visit http://www.sorrentotherapeutics.com

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the safety and efficacy of an adipose-derived allogeneic MSC product in patients with COVID-19 and in respiratory distress; the clinical testing of an adipose-derived allogeneic MSC product; the expected enrollment of the Phase 1 trial; the potential commencement of any future clinical trials for an adipose-derived allogeneic MSC product; the ability of an adipose-derived allogeneic MSC product to work as a stand-alone therapy or in synergy with our other product candidates; the ability of an adipose-derived allogeneic MSC product to support healing and reduce the long-term effects associated with pulmonary tissue damage for COVID-19 patients; our ability to provide a supportive therapy for COVID-19 patents using an adipose-derived allogeneic MSC product; the ability of an adipose-derived allogeneic MSC product to potentially save lives of COVID-19 patients and to potentially minimize the long-term effects of COVID-19; our ability to cover all stages of the continuum of care for COVID-19; and our potential position in the antiviral industry. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries', affiliates and partners technologies and prospects and collaborations with partners, including, but not limited to risks related to seeking regulatory approval for any adipose-derived allogeneic MSC product; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in the execution of its COVID-19 therapeutic product candidate strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations

Alexis Nahama, DVM (SVP Corporate Development)

Telephone: 1.858.203.4120

Email: mediarelations@sorrentotherapeutics.com

Sorrento and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.G-MAB, COVI-GUARDTM, COVI-SHIELD, COVI-AMG, COVIDTRAP, T-VIVA-19, COVI-MAB, ACE-MAB, COVI-TRACK, COVI-STIX and COVI-TRACE are trademarks of Sorrento Therapeutics, Inc.

ZTlido is a trademark owned by Scilex Pharmaceuticals Inc.All other trademarks are the property of their respective owners. 2020 Sorrento Therapeutics, Inc. All Rights Reserved.

Go here to read the rest:
Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue...

Read More...

AIVITA Biomedical’s Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Science – PRNewswire

Thursday, October 15th, 2020

IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ --AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and COVID-19, announced today the publication of the peer-reviewed manuscript, "Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction,"in the journal Investigative Ophthalmology & Visual Science. The study, led by researchers at AIVITA Biomedical and the Sue & Bill Gross Stem Cell Research Center of the University of California, Irvine, used 3D-retina organoids generated from human stem cells developed by AIVITA to provide insight into the potential use of transplanted retina organoids as a therapeutic option for blinding diseases.

In the study, transplanted retina organoid sheets were examined to determine if human stem cell-derived photoreceptors coulddevelop, survive and function in vivo without the support of healthy retina pigment epithelium (RPE). Visual function was examined through a variety of tests, including optokinetic testing (OKT), electroretinogram (ERG), and superior colliculus (SC) brain recording. These tests concluded that retina organoid transplantations demonstrated significant improvement in visual function compared to non-surgery and sham surgery controls, supporting the application of AIVITA's stem cell technologies in visual disease therapeutics.

"Leveraging our expertise in stem cell growth and differentiation, I'm excited to see the promise of our technology platform in potential therapeutics for vision loss," said Hans Keirstead, Ph.D., chief executive officer of AIVITA and a contributing author to the paper. "To our knowledge, this study is the first to show that it's possible for photoreceptors derived from stem cells to survive and function after transplantation when a host has a dysfunctional RPE."

This work is supported by funding from the California Institute for Regenerative Medicine (CIRM) and National Institutes of Health (NIH).

About AIVITA Biomedical AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITA's skin care products support the treatment of people with cancer.

SOURCE AIVITA Biomedical, Inc.

More here:
AIVITA Biomedical's Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Science - PRNewswire

Read More...

Was Trump’s Regeneron ‘Cure’ Developed Using Stem Cells and Fetal Tissues? – Snopes.com

Thursday, October 15th, 2020

As governments fight the COVID-19 pandemic, Snopes is fighting an infodemic of rumors and misinformation, and you can help. Read our coronavirus fact checks. Submit any questionable rumors and advice you encounter. Become a Founding Member to help us hire more fact-checkers. And, please, follow the CDC or WHO for guidance on protecting your community from the disease.

As the world raced to find a treatment that would alleviate the global pressure of the coronavirus pandemic, U.S. President Donald Trump contracted the virus in early October 2020 and developed COVID-19, the respiratory disease caused by SARS-CoV-2. In the days following his diagnosis and public release from Walter Reed Hospital, where he received world-class treatment, Trump touted the powers of a miracle drug called Regeneron, which he promised to make available to the American people.

A video shared in tweet by the president on Oct. 7 claimed that Regeneron was a cure.

I spent four days there [at Walter Reed] and I went in, I wasnt feeling so hot. And within a very short period of time, they gave me Regeneron. Its called Regeneron. And other things too but I think this was the key. But they gave me Regeneron, and it was like, unbelievable. I felt good immediately. I felt as good three days ago as I do now.

So, I just want to say, we have Regeneron. We have a very similar drug from Eli Lilly, and theyre coming out and were trying to get them on an emergency basis. Weve authorized it. Ive authorized it. And if youre in the hospital and youre feeling really bad, I think were going to work it so that you get them and youre going to get them free.

Shortly after the president praised what he deemed a cure for his COVID-19 infection, some social media users pushed the claim that the drug Trump was given was developed using fetal tissue a practice in direct conflict with the administrations pro-life platform.

To clarify, Trump was treated with REGN-COV2, a novel anti-viral antibody cocktail created by Regeneron Pharmaceuticals, a New York-based company that has openly stated it uses stem cell and fetal tissues as part of its research and development on new pharmaceutical treatments. This knowledge, and open support from a pro-life president, incited social media pushback from users who argued that the companys use of stem cells and fetal tissues for scientific research goes against pro-life platforms and policies.

REGN-COV2 is a combination of two human-made proteins, or monoclonal antibodies, known as REGN10933 and REGN10987. These two monoclonal antibodies were specifically designed to block the ability of SARs-CoV-2 to infect human cells. The biotechnology company further went on to describe the development of REGN-COV2 as follows:

To develop REGN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the companys VelocImmune mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19. The two potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the viruss spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population.

While it is true that Regeneron has used stem cells for some of its research, no human stem cells or human embryonic stem cells were used in the development of REGN-COV2, according to Alexandria Bowie, a spokesperson for the company. An April 2020 statement issued by Regeneron confirmed that research using stem cells helps its scientists model complex diseases, test new drug candidates, and lead to scientific insights that may help spur the creation of new medicines but the company contends that embryonic cells were not used in the production of REGN-CO2.

In short: we did not use human stem cells or human embryonic stem cells in the development of REGN-COV2, Bowie told Snopes in an email.

But its not quite that cut and dried.

In the research and development of pharmaceutical therapeutics, many companies turn to what is known as a cell line. These are cultures of human or animal cells that are derived from a living organism and cultured and propagated repeatedly, and, in some cases, used indefinitely. The development of REGN-COV2 utilized HEK293T a cell line that is derived from human fetal embryonic kidney tissues to create a pseudovirus that mimics a spike Protein found in SARS-CoV-2 in order to test the drugs ability to neutralize and ultimately treat the novel coronavirus.

HEK293s are considered immortalized cells (not stem cells) and are a common and widespread tool in research labs. This cell line was originally derived by adenovirus transformation of human embryonic kidney cells in 1977, explained Bowie, adding that HEK293 were further transformed at Stanford in the 1980s with SV40 large T antigen, a solution that is used by researchers to initiate and maintain DNA replication necessary for creating cell lines.

Fetal tissues were not directly used n the development of REGN-COV2, but cell lines from decades-old embryonic kidney tissues were. Fetal tissues are used to develop cell lines. Embryonic stem cells, on the other hand, are different than adult stem cells in that they are undifferentiated and regenerative cells, which means that they have not been assigned a key task in the human body. As such, researchers have uncovered ways to direct their use in creating human tissues that allow for a variety of uses, including testing new pharmaceuticals.

Opposition to the use of fetal tissue and embryonic stem cell research has been at the heart of the pro-life platform due to the way in which these cells are obtained and its association with using living fetuses either inside (in utero) or outside of the uterus (ex utero). Pro-life groups like March for Life have even gone so far as to pressure the Trump administration to halt funding for research that requires aborted fetal organs and tissues. In summer 2019, the president required any federally funded research using fetal tissue to undergo an ethics review, and has since stocked his cabinet with other similarly-minded officials.

REGN-COV2 is currently in late-stage clinical trials for various populations, including non-hospitalized and hospitalized patients as well as for the potential prevention in individuals who may have had close household exposure to COVID-19. According to a news release published on Sept. 29, the company announced that the antibody cocktail was shown to reduce the viral load and alleviate symptoms in non-hospitalized patients with COVID-19. REGN-COV2 also showed positive trends in reducing medical visits. However, it is important to note that the research included a relatively small sample size of just 275 patients.

The greatest treatment benefit was in patients who had not mounted their own effective immune response, suggesting that REGN-COV2 could provide a therapeutic substitute for the naturally-occurring immune response. These patients were less likely to clear the virus on their own and were at greater risk for prolonged symptoms, said Regeneron President and Chief Scientific Officer Dr. George D. Yancopoulos in a statement.

As of Oct. 12, Regeneron had submitted an emergency use authorization (EUA) to the U.S. Food and Drug Administration in early October, and noted REGN-COV2s early, promising clinical data paired with the continued, pressing unmet need of COVID-19 meets the FDA standard for emergency use authorization.

Regeneron told Snopes that it cant speculate on potential timing for an EUA. We will update when such is available.

See the article here:
Was Trump's Regeneron 'Cure' Developed Using Stem Cells and Fetal Tissues? - Snopes.com

Read More...

UofL-born company secures an additional $115 million to advance cell therapy – uoflnews.com

Thursday, October 15th, 2020

A company born at the University of Louisville has raised an additional $115 million to further develop a therapy that could improve the lives of kidney transplant recipients.

The company, Talaris Therapeutics Inc., plans to use the series B funding to support a Phase 3 clinical trial the last step before applying for FDA approval. This follows a $100 million series A funding round announced last year to hire staff and initiate the trial.

Talaris recently began dosing patients in that trial of the unique cell therapy, called FCR001, which allows living-donor kidney transplant recipients to stay off immunosuppression drugs they would otherwise need for the rest of their lives.

Immunosuppressants help prevent rejection of the transplanted organ, but can cause side effects, including high blood pressure, diabetes, high cholesterol, neurological effects, increased risk of infection and decline in kidney function over time.

This technology could help transplant patients live fuller, healthier lives,said UofL Executive Vice President for Research and Innovation, Kevin Gardner.This UofL research, in the hands of strong industry partners and backed by investors, is a big step in advancing our health.

FCR001 consists of stem cells taken from the organ donor and processed at the Talaris facility, then infused into the organ transplant recipient. The goal is to create a durable dual immune system (part donor-derived and part recipient) in the transplant recipient. These two immune systems coexist, recognizing both the recipients own body as well as the donated organ as self.

The new funding also will advance aplanned Phase 2 trial of FCR001 in diffuse systemic sclerosis, a severe form of the rare autoimmune disease scleroderma.

Talaris, formerly known as Regenerex LLC, was founded by UofL researcher and innovator Suzanne Ildstad to commercialize the pioneering work of her team at the university. She now serves as Talaris chief scientific officer.

This financing moves us one step closer to helping organ transplant recipients no longer be dependent on immunosuppressive drugs, resulting in a greatly improved quality of life, Ildstad said of the earlier Phase 3 trial financing. The support and research infrastructure at UofL have been invaluable in our journey to this important juncture.

In an earlier Phase 2 trial, FCR001 allowed 70% of living donor kidney transplant patients durably to be weaned off all of their immunosuppression treatments.

The Phase 3 trial is expected to enroll 120 adult living donor kidney transplant recipients at multiple sites across the U.S. To date, the trial has been initiated at five clinical sites around the country.

Read more here:
UofL-born company secures an additional $115 million to advance cell therapy - uoflnews.com

Read More...

Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome…

Thursday, October 15th, 2020

Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite

"Novellus's iMSCs have the potential to be a breakthrough in the field of cellular therapy for acute respiratory conditions because of their high potency as demonstrated in our pre-clinical studies, as well as our ability to cost-effectively provide high doses and repeat doses." said Myron Holubiak, CEO of Citius.

"We are excited to be developing iMSCs because of their promise to save lives and reduce long term sequelae in patients with devastating respiratory diseases such as ARDS caused by COVID-19," said Matt Angel, Chief Science Officer of Novellus. He continued, "Our iMSCs have multimodal immunomodulatory mechanisms of action that make them promising for treatment of acute respiratory diseases."

About Novellus Therapeutics LimitedNovellus is a pre-clinical stage biotechnology company developing engineered cellular medicines using its patented non-immunogenic mRNA, high-specificity gene editing, mutation-free & footprint-free cell reprogramming and serum-insensitive mRNA lipid delivery technologies. Novellus is privately held and is headquartered in Cambridge, MA. For more information, please visit http://www.novellustx.com.

About NoveCite, Inc.NoveCite, Inc. is a newly formed subsidiary of Citius Pharmaceuticals, a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

Contact: [emailprotected]

SOURCE Novellus Therapeutics

Read more:
Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome...

Read More...

Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion -…

Thursday, October 15th, 2020

Gosselies, Belgium, 14 October 2020, 7am CEST BONE THERAPEUTICS(Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces positive 24-month follow-up results for the Phase IIa study with the allogeneic cell therapy product, ALLOB, in patients undergoing lumbar spinal fusion procedures.

The 24-month data show a high percentage of successful lumbar vertebrae fusion of 90%. Patients also continue to experience important clinical improvements in function and pain, from as early as six months after treatment, up to the 24-month follow-up period.

Degenerative spine disorders have a major impact on the quality of life of patients. These impacts include decreases in the stability of the spine and pain in motion,said Dr. Alphonse Lubansu, M.D., Head of the Spinal Clinic, Erasme University Hospital, Universit libre de Bruxelles. The 24 month follow-up data of this Phase IIa clinical trial have demonstrated that patients treated with ALLOB in spinal fusion procedure show a high incidence in fusion, and benefit from a sustained, clinically meaningful improvement in function and pain throughout the 24 months following treatment together with a good safety profile. These results show that ALLOB in combination with the standard spine fusion surgery could be a promising treatment option to address the currently unmet needs of these patients.

This positive data forlumbar spinal fusion complementsthe strong Phase I/IIa results from ALLOB in patients with delayed union fractures,said Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics. These studies provide promising clinical evidence for the potential ofBone Therapeuticsunique allogeneic cell therapy platform to address high unmet medical needs in orthopaedics and bone related disorders. We will now hold discussions with global regulators and our partners to explore a variety of options for the next stages of clinical development for ALLOB in different orthopedic indications, while pursuing the phase IIb study of ALLOB in difficult tibial fractures.In addition, theclinical results provide further evidence for the expansion of ALLOB and our platform of differentiated MSCs to other indications.

The multi-center, open-label proof-of-concept Phase IIa study was designed to evaluate the safety and efficacy of ALLOB administered, procedure in which an interbody cage with bioceramic granules mixed with ALLOB is implanted into the spine to achieve fusion of the lumbar vertebrae. The main endpoints of the 24-month follow-up analysis included safety and radiological assessments to evaluate vertebrae fusion (continuous bone bridges) and clinical assessments to evaluate improvement in patients functional disability as well as reduction in back and leg pain. The study evaluated 30 patients treated with ALLOB, 29 patients attended the 24-month visit.

Radiological data was collected from CT-scans at 24 months and assessed by three external readers. It showed a successful fusion of the lumbar vertebrae in 27 out of 30 patients (90%). In addition, the remaining 3 patients showed radiological evidence of bone formation. Treatment with ALLOB also resulted in a clear and statistically significant clinical improvement in function and reduction in pain over the 24-month follow-up period. Functional disability improved from the pre-treatment baseline to 24-month by a mean score of 60% (p<0.001) on the Oswestry Disability Index(1). Back and leg pain were strongly reduced by 57 to 62% (p<0.001) and 68 to 70% (p<0.001) respectively compared to pre-treatment baseline. Treatment with ALLOB was generally well-tolerated by the patients, consistent with previous reported results.

(1)The Oswestry Disability Index (ODI) is an index derived from the Oswestry Low Back Pain Questionnaire used by clinicians and researchers to measure a patients permanent functional disability. This validated questionnaire was first published by Jeremy Fairbank et al. in Physiotherapy in 1980. ODI score of 0%-20%: minimal disability; 21%-40%: moderate disability; 41%-60%: severe disability; 61%-80%: crippled; 81%-100%: bed bound.

About Spinal Fusion

Due to ageing populations and sedentary lifestyles, the number of people suffering from degenerative spine disorders continues to increase. Today, spinal fusion procedures are performed to relieve pain and improve patient daily functioning in a broad spectrum of degenerative spine disorders. Spinal fusion consists of bridging two or more vertebrae with the use of a cage and graft material, traditionally autologous bone graft or demineralised bone matrix placed into the intervertebral space for fusing an unstable portion of the spine and immobilizing a painful intervertebral motion segment. Over 1,000,000 spinal fusion procedures are performed annually in the US and EU, of which half at lumbar level and the market is growing at a rate of 5% per year. Although spinal fusion surgery is routine, non-fusion, slow progression to fusion and failure to eliminate pain are still frequent with up to 35% of patients not being satisfied with their surgery.

About ALLOB

ALLOB is the Companys off-the-shelf allogeneic cell therapy platform consisting of human allogeneic bone-forming cells derived from cultured bone marrow mesenchymal stem cells (MSC) from healthy adult donors, offering numerous advantages in product quality, injectable quantity, production, logistics and cost as compared to an autologous approach. To address critical factors for the development and commercialisation of cell therapy products, Bone Therapeutics has established a proprietary, optimised production process that improves consistency, scalability, cost effectiveness and ease of use of ALLOB. This optimized production process significantly increases the production yield, generating 100,000 of doses of ALLOB per bone marrow donation. Additionally, the final ALLOB product will be cryopreserved, enabling easy shipment and the capability to be stored in a frozen form at the hospital level. The process will therefore substantially reduce overall production costs, simplify supply chain logistics, improve patient accessibility and facilitate global commercialisation. The Company will implement the optimized production process for all future clinical trials with ALLOB.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement.

Bone Therapeutics core technology is based on its cutting-edge allogeneic cell therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company is ready to start the phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics cell therapy products are manufactured to the highest GMP standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available atwww.bonetherapeutics.com.

For further information, please contact:

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0)71 12 10 00investorrelations@bonetherapeutics.com

For Belgian Media and Investor Enquiries:BepublicCatherine HaquenneTel: +32 (0)497 75 63 56catherine@bepublic.be

International Media Enquiries:Image Box CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20 8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: +33 (0)1 44 71 94 94bone@newcap.eu

For US Media and Investor Enquiries:LHA Investor RelationsYvonne BriggsTel: +1 310 691 7100ybriggs@lhai.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Read the rest here:
Bone Therapeutics' allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion -...

Read More...

Thalassemia Treatment Market projected to expand at a CAGR of 7.9% from 2018 to 2026 – The Daily Chronicle

Wednesday, September 30th, 2020

Transparency Market Research (TMR)has published a new report titled, Thalassemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026.According to the report, theglobal thalassemia treatment marketwas valued at US$ 842.0 Mn in 2017 and is projected to expand at a CAGR of 7.9% from 2018 to 2026. Increase in R&D investment by key players for developing new drugs for treating thalassemia and rise in demand for chelating therapy are anticipated to fuel the growth of the global market from 2018 to 2026. Asia Pacific and Middle East & Africa are expected to dominate the global market owing to increase in prevalence of thalassemia disorder and high adoption of chelation therapy & blood transfusion for treatment by doctors as well as patients. The market in Asia Pacific is projected to expand at the fastest CAGR during the forecast period. Growth of the market in the region is attributed to large base of private clinics and hospitals, rise in number of thalassemia population requiring chelation therapy services after spleen surgery, and surge in adoption of blood transfusion among patients. The thalassemia treatment market in Latin America is likely to expand at a moderate growth rate during the forecast period.

Request Brochure for Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=44462

Value Added Features in Thalassemia Treatments to Propel Global Market

The global thalassemia treatment market is projected to be driven by value added features offered by various thalassemia drug manufacturing companies in order to streamline the day to day work flow and increase revenue. The thalassemia treatment provides limited range of features and benefits ranging from patient pain heeling remedies to treatment procedures. For instance, very less number of people go for the much beneficial chelation therapy. These features help physicians and nurses to streamline the chelation therapy required for patients to maintain their daily workflow efficiently and effectively. Key players offering thalassemia treatment are coming up with value added features such as bone marrow transplantation, stem cell regeneration, gene editing methodologies, and effective modality features used for drug manufacturing along with creating a prominent candidate molecule for drugs. These features can reduce the overall operating cost and improve the overall effectiveness and efficiency of treatment practices. Companies are focusing on the development of combined drug therapy in their system to effectively integrate chelating therapy or other treatment procedure at an affordable cost. These value added features save time for physicians and help improve thalassemia patient survival performance.

Request for Analysis of COVID19 Impact on Thalassemia Treatment Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=44462

Chelation Therapy to be Highly Lucrative Segment

Traditionally, blood transfusion based on type of thalassemia treatment was the most commonly used procedure among thalassemia patients. This treatment type was associated with availability of donor and cost of treatment procedure. Moreover, chelation therapy based on thalassemia treatment are priced on perpetual license model and are expensive. Chelation therapy treatment enables patients to practice intensive therapy to treat acute iron overload leading to 90% recovery among thalassemia patients. These chelation therapy based treatments address specific challenges faced during the treatment procedure. The chelation therapy treatment facilitates benefits such as pain relief, and increase in motion of blood flow among patients.

Asia Pacific Presents Significant Opportunities

North America and Europe accounted for major share of the global thalassemia treatment market in 2017 and are likely to gain market shares by 2026. High rate of immigration from tropical regions, increasing health care budgets by governments, and government initiatives to promote thalassemia treatment technique contributed to the leading share of these regions. Asia Pacific is projected to be the most attractive market for thalassemia treatment, with highest attractiveness index. The market in Asia Pacific is expected to expand at a high CAGR of 9% during the forecast period due to large number of thalassemia patients opting for chelation therapy in developing countries such as India and China. Well-established health care facilities, medical tourism for treatment of thalassemia, and high adoption of blood transfusion safety technique in countries such as Turkey and GCC Countries are likely to drive the market in Middle East & Africa. The market in Latin America is poised to expand at a moderate growth rate during the forecast period.

Buy Thalassemia Treatment Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=44462&ltype=S

Trend of R&D among Leading Players to Increase Geographic Presence

The report also provides profiles of leading players operating in the global thalassemia treatment market. bluebird bio, Inc., Acceleron Pharma, Inc., Novartis AG, Celgene Corporation, and Shire plc (Takeda Pharmaceuticals) are the leading players operating in the global market. Companies operating in the thalassemia treatment market aim to increase geographic presence and research & development through strategic acquisitions and collaborations with leading players in respective domains and region. In December 2017, Shire plc committed to pay approximately US$ 1,409.9 Mn to contract vendors for administering and executing clinical trials. Other prominent players operating in the global thalassemia treatment include Incyte Corporation, Kiadis Pharma, Gamida Cell, Celgene Corporation, and Bellicum Pharmaceuticals.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

See the original post:
Thalassemia Treatment Market projected to expand at a CAGR of 7.9% from 2018 to 2026 - The Daily Chronicle

Read More...

Indian Biotechnology Market Market scrutinized in the new analysis – WhaTech

Tuesday, September 22nd, 2020

Indian Biotechnology Market Size, Share & Trends Analysis Report by Type (Healthcare, Crop Production and Agriculture, Industrial, Natural Resources & Environment, and Others) and Forecast 2020-2026

Indian biotechnology market is estimated to grow significantly at a CAGR of 8.1% during the forecast period. The increasing healthcare expenditure and increasing funding in cell-based research in the country are further supporting the biotechnology market in the country. The Government of India has taken some steps to promote cell harvesting techniques in the country and have set up numbers of stem cell banks throughout the country.

Report: http://www.omrglobal.com/requestogy-market

According to International Brand Equity Foundation (IBEF), the Indian healthcare market can increase three-fold to nearly $133.4 billion in 2022. The country is experiencing growth of around 22-25% in medical tourism. Various hospital chains such as Apollo Hospitals and Global Healthcare Enterprise are growing significantly in India due to a huge prevalence of cancer and related diseases. Private hospitals are expanding their business to provide a wide range of diagnostic tests and applications to a massive pool of cancer patients including foreign patients during medical tourism.

Browse for Full Report Description atwww.omrglobal.com/industrogy-market

The Indian biotechnology market is classified on the basis of type.

Based on type, the market is segmented into healthcare, crop production and agriculture, industrial, natural resources & environment, and others. The companies which are contributing to the growth of the Indian biotechnology market include Amgen Inc., Novo Nordisk A/S, CSL Ltd., Bristol-Myers Squibb Co., AstraZeneca PLC, Merck & Co., Inc., Johnson & Johnson Services Inc., and Pfizer Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Market Segmentation

Indian Biotechnology Market by Type

Company Profiles

Report: http://www.omrglobal.com/report-ogy-market

This email address is being protected from spambots. You need JavaScript enabled to view it.

See the original post here:
Indian Biotechnology Market Market scrutinized in the new analysis - WhaTech

Read More...

Why Are There Only 10 Cell and Gene Therapies in… – Labiotech.eu

Tuesday, September 22nd, 2020

There is a lot of talk about how cell and gene therapy are going to change medicine, so why have only a few of them reached the market?

Over the last decade, only 14 advanced therapy medicinal products (ATMPs) that is, cell and gene therapies have received approval in Europe. With four withdrawals, only 10 of them still have a valid marketing authorization.

That is a stark contrast with the fact that there have been over 500 clinical trials using ATMPs in the EU since 2009. But the reality is that its a bit too soon to be expecting results many of these technologies are brand new and decades-old discoveries are only just reaching the market. For example, the development of Strimvelis, approved in 2016, took more than 20 years. The approval of Chondrocelect in 2009 took nine years since its developer, TiGenix, was founded.

Holoclar initially seemed like an exceptional case: research and development started around 1996 and the first clinical results were published just a year later. But one of its developers, Graziella Pellegrini, reported the product was under development for a total of 25 years. So those excited about CRISPR therapies, based on a gene-editing technology that was only developed in 2012, will still have to wait.

If the time scale wasnt daunting enough, research and development also burns cash quickly.A big chunk of the total money invested goes into meeting the quality, safety, and efficacy standards set by the regulatory authorities. This step seems to represent one of the biggest challenges for developers.

In fact, when regulations for ATMPs were first released in Europe, it appeared that authorities and researchers were on different wavelengths. In 2007, new European Union (EU) regulations on advanced therapies came in, which added more, very frustrating years to the development, said Pellegrini. It seemed that we had to start from scratch.

Thanks to frequent stakeholder consultations, these requirements are constantly being simplified, following the EMAs goal of fostering development and expanding patient access. But even with dynamic regulations, some products may only be authorized at thenational level and not for the whole continent.

For example, there is a dedicated pathway to exceptionally approve and commercialize ATMPs only locally as hospital exemptions. This status includes several limitations: this designation is only for non-routine products and those custom-made for individual patients, and importing or exporting them is illegal which can lead to the dangerous practice of stem cell tourism.

It seems complicated enough to reach the market with a cell or gene therapy, but the struggle isnt over at that point. The EMA can still withdraw a marketing application due to safety issues or if the company doesnt apply (and pay) for a renewal of the marketing authorization after five years.

That was the case of Glybera, the first gene therapy to receive approval in Europe. Its developers decided to not renew its market authorization after the therapys commercial failure in Europe and difficulties reaching the US market. With a very small target market and a price of one million euros, it was the most expensive treatment back in 2012, making it hard to convince governments and private insurance companies to pay for it.

In fact, only one person was treated with Glybera after its approval. Elisabeth Steinhagen-Thiessen, the doctor who prescribed it, had a lengthy fight with the German authorities and the insurance company to make them pay for the treatment. After the withdrawal, three doses left were given to patients for one euro each.

A big challenge for cell and gene therapies is that they often target conditions that affect a very small number of patients. Pharmaceutical companies are not much interested in unprofitable rare disease, commented Pellegrini.

In the case of Strimvelis, there are only about 14 people per year in Europe and 12 in the US diagnosed with its target disease, a rare form of genetic immune deficiency called ADA-SCID. The numbers are better for Holoclar, with around 1,000 people annually in Europe being eligible burn victims who have become blind but whose eyes have not been too extensively destroyed. Still,it is far short of a blockbuster.

There are exceptions, such as Imlygic, a therapy from Amgen approved in 2015 for the treatment of late-stage melanoma, with over 56,000 new cases across the EU each year.

Its fair to say that the majority of withdrawals have been made for business reasons, not safety issues. This highlights the fact that receiving EMA approval does not guarantee commercial viability the product can still be an economic failure.

Clearly, we have a lot of lessons to learn from past failure and success stories. As regulators and insurance companies become more familiar with cell and gene therapies, and developers avoid the mistakes made by others in the past, we can expect a future where cell and gene therapies become commonplace and no longer a futuristic hope.

Cover illustration by Elena Resko, images via Pharma Boardroom and the author. This article was published in April 2018 and has since been updated to reflect the latest EMA approvals.

Read the original here:
Why Are There Only 10 Cell and Gene Therapies in... - Labiotech.eu

Read More...

Colorado woman arrested for Assault in the Second Degree and Resisting Arrest – Maui Time

Sunday, September 13th, 2020

On September 11, 2020 at about 5:07 a.m., Tara Trunfio (24), from Colorado, was arrested for Assault in the Second Degree and Resisting Arrest.

Investigation reveals that on September 11, 2020 at about 3:46 a.m., Hana Patrol officers were assigned to the 4590 Hana Highway, regarding a female with a stab wound. It was alleged that Trunfio had earlier stabbed the victim while at the end of Ulaino Road.

Trunfio was located at the very end of Uluino Road. After advisement of her Constitutional Rights and being told she was under arrest, Trunfio physically and verbally resisted. A struggle ensued. Trunfio was taken into custody and transported to the Hana Police Station. She was assessed by Medic 6. Neither Trunfio nor Officers sustained or reported any injuries as a result of this incident.

Trunfio was later transported to the Wailuku Receiving Desk for processing.

On September 11, 2020 at about 11:01 a.m., Trunfio was formally charged for Assault in the Second Degree and Resisting Arrest. Her bail is set at $7,000. As of 12:15 p.m., she remains in Police Custody.

Press Release 9-120-20 Maui Police Department

comments

Read more:
Colorado woman arrested for Assault in the Second Degree and Resisting Arrest - Maui Time

Read More...

Page 11234..10..»


2021 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick